Dose administered and dosing interval among patients who developed high-titer versus low-titer inhibitors up to inhibitor development∗
| Median (range) . | High-titer inhibitor (n=14) . | Low-titer inhibitor (n=14) . |
|---|---|---|
| Total number of EDs at inhibitor development | 9.0 (4.0-14.0)† | 12.0 (1.0-53.0) |
| Mean dose per infusion (IU/kg) | 44.1 (28.0-81.2) | 42.3 (24.8-69.9) |
| Mean dosing interval (d) | 7.6 (3.3-63.5) | 7.5 (1.7-69.0) |
| Factor consumption per week (IU/kg per week)‡ | 39.1 (5.0-116.6) | 33.3 (3.2-293.8) |
| Median (range) . | High-titer inhibitor (n=14) . | Low-titer inhibitor (n=14) . |
|---|---|---|
| Total number of EDs at inhibitor development | 9.0 (4.0-14.0)† | 12.0 (1.0-53.0) |
| Mean dose per infusion (IU/kg) | 44.1 (28.0-81.2) | 42.3 (24.8-69.9) |
| Mean dosing interval (d) | 7.6 (3.3-63.5) | 7.5 (1.7-69.0) |
| Factor consumption per week (IU/kg per week)‡ | 39.1 (5.0-116.6) | 33.3 (3.2-293.8) |
ITI, immune tolerance induction.
Statistical testing was by inhibitor titer (high vs low) using 2-sided Mann-Whitney U test. P values >.05.
ED for 2 patients are not provided because the second high-titer measurement occurred outside the study period. One patient developed an HTI during the pre-ITI period and therefore is not considered for this analysis. One patient initially developed an LTI; however, an HTI was detected shortly after their formal withdrawal from the study (for the reason of lack of home health care). Thus, the patient was considered to have developed an HTI but did not have on-study data related to dosing between LTI and HTI development and is excluded from this analysis.
Dose per week (IU/kg per week) = total dose (IU/kg)/total time (weeks).